Opening

Le capcommundes actionnaires.

An editorial and community platform for shareholders who want to understand, engage with, and dialogue constructively with the companies they own.

Read the manifesto See the companies we cover

Recent activity

Sep 14, 2026Oculis · September 2026 investor conferences: H.C. Wainwright Annual Global Investment (14–16 Sept., company update by CEO Riad Sherif on 14 Sept.), Baird 2026 Global Healthcare (fireside chat on 15 Sept.), Leerink Biopharma Summit (23–25 Sept.); Q3 2026 results on 3 November
Sep 9, 2026Medincell · September 2026 investor conference tour: Morgan Stanley 24th Annual Global Healthcare and H.C. Wainwright 28th Annual Global Investment (14–16 Sept.), Jefferies Healthcare C-Suite Back-to-School Fireside Chat (22 Sept.), BioCentury Annual Grand Rounds Europe in Amsterdam (23–25 Sept.), represented by Dr Grace Kim, Chief Strategy Officer, U.S. Finance
Sep 8, 2026Medincell · publication of the notice of meeting for the 30 September 2026 combined general meeting (Jacou headquarters, 6:00 p.m. CEST) and reminder of the participation terms: written questions until 24 Sept., postal voting forms until 25 Sept., Votaccess platform open from 9 to 29 Sept. (3:00 p.m. CEST)
Sep 1, 2026Medincell · appoints Edna Venneker, MD, as Chief Medical Officer (previously Head of Development and Deputy CMO at Grünenthal)
Aug 26, 2026Medincell · convening notice for the 30 September 2026 combined general meeting published in the BALO (31 resolutions; 6th resolution: Dr Elisabeth Svanberg as director for 4 years, expiry of Virginie Lleu’s term)
Aug 24, 2026Oculis · first patient treated in PIONEER-1 (privosegtor, optic neuritis; FDA BTD and EMA PRIME designations)

II.

On screen

Video

On CapCordia

CapCordia Shareholders' Pact·June 2026

III.

Posture

« We are not an activist fund. We are not trying to impose a vision. We offer common ground — that of an informed shareholder base that understands, questions, and engages. Without aggression, without complacency. »

Read the manifesto

IV.

Approach

Our approach

Three pillars, one standard: quality.

Sourced editorial

Structured company files: thesis, catalysts, risks, calendar. Facts, not noise.

Constructive dialogue

A posture of mutual engagement with management. CapCordia is common ground, not combative activism.

Qualified community

Long-term shareholders who share a rigorous reading of the files and prepare for general meetings.

Coverage

Companies covered

Companies we cover

CapCordia is built around a small number of deeply researched files.

Key partnersTeva · AbbVie

UZEDY® sales FY25-26$215M (+52,5%)

French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. FY 2025-26 marks the acceleration of the transition toward a stable royalty model: UZEDY® (Teva, schizophrenia) generated $215M in net sales (+52.5% YoY), and olanzapine LAI (TEV-‘749) is expected to launch in the United States in Q4 2026.

Biotechnology · Specialty drug deliveryOpen the file

HeadquartersLausanne · Reykjavík

Swiss/Icelandic ophthalmology biotech listed on Nasdaq (OCS). After the DIAMOND pivotal-trial failure (OCS-01 in diabetic macular oedema, 29 May 2026), Oculis is repositioning around neuro-ophthalmology with two assets in registrational trials: licaminlimab (OCS-02) in severe dry eye disease — PREDICT-1 topline expected around year-end 2026 — and privosegtor (OCS-05), a neuroprotective candidate whose programme is expanding from optic neuritis (PIONEER) to acute multiple sclerosis relapses (positive FDA pre-IND feedback in August 2026). In August 2026, Oculis signed the acquisition from Accure Therapeutics of full worldwide ownership of privosegtor (and the preclinical candidate ACT-02), moving from licensee to owner of its lead asset. Cash of $282.3M at 30 June 2026, stated runway into 2H 2029.

Biotechnology · OphthalmologyOpen the file